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Transthyretin is an essential protein responsible for
the transport of thyroid hormones and retinol in human
serum and is also implicated in the amyloid diseases
familial amyloidotic polyneuropathy and senile sys-
temic amyloidosis. Its folding properties and stabiliza-
tion by ligands are of current interest due to their im-
portance in understanding and combating these
diseases. Here we report the solid phase synthesis of the
monomeric unit of a transthyretin analog (equivalent to
127 amino acids) using t-Boc chemistry and peptide li-
gation and its folding to form a functional 54-kDa tet-
ramer. The monomeric unit of the protein was chemi-
cally synthesized in three parts (positions 1–51, 54–99,
and 102–127) and ligated using a chemoselective
thioether ligation chemistry. The synthetic protein was
folded and assembled to a tetrameric structure in the
presence of transthyretin’s native ligand, thyroxine, as
shown by gel filtration chromatography, native gel elec-
trophoresis, transthyretin antibody recognition, and
thyroid hormone binding. Other folding products in-
cluded a high molecular weight aggregate as well as a
transient dimeric species. This represents one of the
largest macromolecules chemically synthesized to date
and demonstrates the potential of protein chemical syn-
thesis for investigations of protein-ligand interactions.
Transthyretin (TTR)1 is a 54-kDa tetramer, which is present
in human plasma (3.6 mM tetramer) and transports thyroid
hormones such as 3,5,39-triiodo-L-thyronine and L-thyroxine
(T4) as well as retinol-binding protein (1, 2). Its structure and
ligand binding capabilities have been characterized by x-ray
crystallography (3–5). Each subunit contains extensive b-sheet
structure and is arranged within a dimer of dimers to form a
compact molecule with two funnel-shaped hormone ligand
binding sites, each defined by a dimer-dimer interface. The
thyroid hormones bind deeply within the hydrophobic binding
channel, their iodinyl moieties residing in hydrophobic pockets
at two different binding sites within the channel (6). Upon
binding of one T4 ligand, the binding affinity for the second
ligand is reduced significantly.
Although the TTR tetramer is inherently very stable (1, 7), in
some circumstances transthyretin has a propensity to form
amyloid fibrils. In diseases such as senile systemic amyloidosis
and familial amyloidotic polyneuropathies, native and mutant
TTR, respectively have been found to form long beta-sheet
based fibrillar structures (8, 9). These amyloid lesions accumu-
late in specific organs and are implicated in their dysfunction
and ultimately the death of the patients. More than 70 separate
mutations that appear to increase the propensity of TTR to
form amyloid structures underlying familial amyloidotic poly-
neuropathy have so far been identified (10–14). It is thought
that the underlying mechanism for TTR fibril formation in-
volves tetramer dissociation to a monomeric conformational
intermediate which self-assembles to form amyloid fibrils. Any
mutation or cellular condition (such as low pH) that tends to
destabilize the tetramer can result in an increased propensity
of the protein to form amyloid fibrils (9, 11).
The ligand binding properties of TTR have become of major
importance recently, with the discovery that certain thyroid
hormone competitors (e.g. 2,4,6-triiodophenol) are able to de-
crease the tendency of TTR to form amyloid fibrils (15, 16).
They are reported to act by binding deeply within the TTR
binding channel at both ligand binding sites and inhibiting the
formation of amyloid by stabilizing the normal fold against the
pathogenic conformational change. A range of nonsteroidal an-
ti-inflammatory drugs are currently being investigated for
their ability to inhibit and reverse amyloid formation (17).
While crystallographic information has revealed the orienta-
tions of several of these drugs bound to TTR, there are many
aspects of the ligand binding that cannot be probed using
crystallographic techniques. These include dynamic aspects of
protein-ligand binding in solution and in the presence of com-
petitors or in the presence of other serum proteins, including
the other thyroid hormone carriers albumin and thyroxine-
binding globulin. For such studies, it is possible that NMR
spectroscopic methods could be employed.
NMR can be used to observe the interaction of a ligand with
particular sites in the protein. Such studies currently depend
upon the assignment of the specific resonances that are per-
turbed by the ligand (18), which limits studies to systems in
which the protein signal of interest is either fortuitously dis-
tinct or has been fully assigned using isotopic labeling and
heteronuclear NMR techniques. In the latter case, this also
requires that the protein is less than about 40 kDa due to the
broad line widths of the NMR signals and large number of
signals that have similar chemical shifts. The problem can be
somewhat reduced by using chemical ligation strategies in
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which just one portion of the protein is isotopically labeled (19).
Of even greater value would be the ability to completely control
the position of the isotopic label in a protein for probing the
ligand interaction.
The current study thus presents the first stage in the devel-
opment of a spectroscopic method for probing a protein-ligand
interaction. The strategy involves the complete synthesis of a
TTR analog using solid phase synthesis and chemical ligation
techniques and refolding of the protein to a tertiary and qua-
ternary structure that approximates the native form. Since the
structure of TTR is known to atomic resolution from x-ray
crystallographic studies, an NMR active probe (i.e. 15N- or
13C-labeled amino acid) may be incorporated at any strategic
position to enable subsequent ligand binding studies to be
manifest in NMR spectra.
The chemical synthesis of proteins of the size of the mono-
meric unit of TTR (127 residues) represents a significant chal-
lenge. In the past, long peptides were synthesized in a stepwise
fashion, as exemplified by human immunodeficiency virus type
1 protease (20) and interleukin-8 (21), but significant purifica-
tion problems resulted in low yields of protein. Currently, the
synthesis techniques for proteins of this size rely on chemos-
elective ligation techniques, where two or more nonprotected
peptides are joined through a highly selective chemical
reaction.
There have been several notable protein syntheses described
using chemoselective ligation techniques that incorporate thio-
ester and thioether surrogate amide bonds. These include the
synthesis of linked heterodimeric basic helix-loop-helix tran-
scription factors (22) and Cpn10 (23), respectively. Recently,
techniques for forming a native amide bond have been applied
to a range of protein types including serine protease inhibitors
(24–26), human II secretory phospholipase A2 (27), and bar-
nase (28, 29).
Native chemical ligation chemistry is only useful provided
there are suitably positioned cysteines. In order to synthesize a
protein like transthyretin without suitably located cysteines, it
becomes necessary to use chemically modified amino acid sub-
stitutes or amino acid mutations. The thioether ligation strat-
egy we use here introduces -NH-CH2-CH2-S-CH2-CO-, which
mimics a two-amino acid subunit closely resembling a glycyl-
glycine (-NH-CH2-CO-NH-CH2-CO-). While the thioether moi-
ety closely resembles the spatial requirements for glycyl-gly-
cine, it may lack potential hydrogen bond donation/acceptor
behavior of the diamino acid unit, thereby potentially introduc-
ing some nonnative structural characteristics.
Here we demonstrate the total chemical synthesis of an
analog of human TTR through the use of the thioether strategy
for the sequential ligation of three peptides. We also show that
this synthetic TTR (henceforth referred to as sTTR) may be
successfully refolded and reconstituted to form a 54-kDa tet-
rameric structure able to bind the thyroid hormone T4. This
represents one of the largest active proteins made synthetically
and provides methodology for future protein-ligand investiga-
tions using NMR spectroscopic techniques.
EXPERIMENTAL PROCEDURES
Chemicals and Reagents—Trifluoroacetic acid, dichloromethane,
N,N-dimethyl formamide, and diisopropylethylamine were from Aus-
pep (Melbourne, Australia). O-Benzotriazol-1-yl-N,N,N9,N9-tetram-
ethyluronium hexafluorophosphate was from Richelieu Biotechnologies
(St. Hyacinth, Quebec Canada). Acetonitrile was from BDH Laboratory
Supplies (Poole, United Kingdom). Acetic acid and chloroacetic acid
were from Ajax chemicals (Auburn, Australia), diethyl ether was from
Fluka Biochemicals (Melbourne, Australia), and mercaptoethanol was
from Sigma. Ethanolamine, N,N-diisopropylcarbodiimide, and bro-
moacetic acid were from Aldrich. Hydrogen fluoride (HF) was pur-
chased from Boc Gases (Brisbane, Australia). The N-Boc-protected L-
amino acids Ala, Gly, Ile, Leu, Phe, Pro, Val, Arg(p-toluenesulphonyl),
Asp(O-cyclohexyl), Asn(xanthyl), Glu (O-cyclohexyl), His(dinitrophe-
nyl), Lys(2-chlorobenzyloxycarbonyl), Ser(benzyl), Thr(benzyl), Trp-
(formyl), Tyr(2-bromobenzyloxycarbonyl) were purchased either from
NovaBiochem (La Jolla, CA) or Bachem (Switzerland). Human serum
was supplied by the Red Cross Blood Bank (Melbourne, Australia).
Equipment—Analytical and preparative HPLC was carried out using
a Waters HPLC system composed of a model 600 solvent delivery
system 600E controller and model 484 detector. Vydac C18 columns,
analytical (4.6 3 250 mm) at a flow rate of 1 ml/min, semipreparative
(10 3 250 mm) at a flow rate of 3 ml/min, and preparative (22 3 250
mm) at a flow rate of 8 ml/min, were used. All peptides were purified
using linear gradients of 0.1% aqueous trifluoroacetic acid (solvent A)
and 90% aqueous acetonitrile 0.09% trifluoroacetic acid (solvent B).
Mass spectral data were collected using a PerkinElmer Sciex
(Toronto, Canada) API III biomolecular mass analyzer ion-spray mass
spectrometer equipped with an ABI 140B solvent delivery system. Raw
data were analyzed using the program MassSpec (PerkinElmer Sciex).
Calculated masses were obtained using the program MACROMASS
(Sunil Vemuri and Terry Lee, City of Hope, Durate, CA).
Enhanced Chemiluminescence kit was from Amersham Pharmacia
Biotech, x-ray film was from Eastman Kodak Co., methylcellulose and
activated charcoal (Norit PN.5) were from BDH, L-[125I]thyroxine (1.2
Ci/mg) was from PerkinElmer Life Sciences (NEN Dupont), SepPak
C-18 cartridges were from Millipore Corp., and thin layer chromatog-
raphy plates were from Merck. All reagents were of analytical grade.
Native Human TTR—Native human TTR was isolated from serum
using an adapted version of the method described by Dwulet and
Benson (30).
Peptide Synthesis—Peptides were synthesized using the rapid man-
ual O-benzotriazol-1-yl-N,N,N9,N9-tetramethyluronium hexafluoro-
phosphate in situ neutralization synthesis technique (31) or using the
same technique on a modified ABI 430A peptide synthesizer (32). The
thioether resins were prepared according the methods of Englebretsen
et al. (33), initially on amino methyl resins and then subsequently
Boc-amino acid-Pam resins (ABI). The bromoacetyl and chloroacetyl
groups at the amino termini of peptides were coupled using the sym-
metrical anhydride formed from reaction with N,N-diisopropylcarbodi-
imide. The dinitrophenyl group was removed using 20% mercaptoeth-
anol in 10% diisopropylethylamine/N,N-dimethyl formamide solution
for two or three 30-min treatments. The Trp formyl deprotection was
carried out using ethanolamine prior to HF cleavage.
Peptide resins were cleaved using HF with p-cresol and p-thiocresol
as scavengers at 25 to 0 °C for 1–2 h. The HF was removed in vacuo, the
peptide product was triturated with cold diethyl ether (3 3 50 ml), and
the precipitated peptide was collected and dissolved in 50% acetonitrile
with 0.1% trifluoroacetic acid.
The crude peptides were purified by reverse phase (RP)-HPLC, and
fractions were collected and analyzed by analytical RP-HPLC and elec-
trospray mass spectrometry (ESMS). Fractions containing the purified
peptide were combined and lyophilized.
Solid Phase Synthesis of Br-Ac-PRRYTIAALLSPYSYSTTAVVT-
NPKE-OH (Bromoacetyl-102–127 TTR) (I)—Peptide I (see Fig. 2) was
synthesized on a Boc-Glu(O-benzyl)-Pam-polystyrene resin (ABI) on a
0.5-mmol scale. Amino acid couplings averaged 99.5% efficiency. N-Boc
deprotection and coupling of bromoacetic acid followed by HF cleavage
gave the crude peptide, which was purified by preparative HPLC using
a linear gradient of 0–70% B. The peptide was then analyzed by HPLC
and ESMS. The purified peptide was characterized as the desired
product (I) by ESMS (observed mass 5 3021 6 0.3; calculated for C133
H210 N34 O41 Br1 5 3021.24 (average isotope composition)).
Solid Phase Synthesis of Cl-Ac-ELHGLTTEEEFVEGIYKVEI-
DTKSYWKALGISPFHEHAEVVFTAND-NH-CH2-CH2-SH (Chloro-
acetyl-54–99-NH-CH2-CH2-SH) (II)—The C-terminal thiol peptide II
was manually synthesized using the thiol linker attached to Boc-Ala-
Pam resin in the first synthesis and then Boc-Gly-Pam resin for the
second. The average amino acid coupling for the syntheses was 99.5 and
99.6%, respectively. The dinitrophenyl protecting group was removed
followed by N-Boc and formyl group removal. The chloroacetyl group
was coupled, and then the peptide was cleaved by HF. The crude
peptide was purified by preparative HPLC using a linear gradient of
0–70% B and then analyzed by HPLC and ESMS. The purified peptide
was characterized as the desired product (II) by ESMS (observed
mass 5 5416.46 6 1.1; calculated for C246 H364 N58 O76 S1 Cl1 5 5417.46
(average isotope composition)).
Solid Phase Synthesis of H-GPTGTGESKAPLMVKVLDAVRGSPA-
INVAVHVFRKAADDTWEPFASGKTSE-NH-CH2-CH2-SH (1–51-NH-
CH2-CH2-SH) (III)—The C-terminal thiol peptide III was synthesized
using machine-assisted synthesis. The peptide was synthesized using
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the thiol linker attached to Boc-Gly-Pam resin. The average amino acid
coupling was 99.6% (1st coupling) for the synthesis, which was rou-
tinely double coupled. The dinitrophenyl protecting group was removed,
followed by N-Boc and then the formyl group. The peptide was cleaved
from the resin, and the crude peptide was purified by preparative HPLC
using a linear gradient of 0–70% B. The peptide was then analyzed by
HPLC and ESMS. The purified peptide was characterized as the de-
sired product (III) by ESMS (observed mass 5 5355 6 1.0; calculated for
C236 H379 N66 O72 S2 5 5357.14 (average isotope composition)).
Formation of Cl-Ac-ELHGLTTEEEFVEGIYKVEIDTKSYWK-
ALGISPFHEHAEVVFTAND-NH-CH2-CH2-S-CH2-CO-PRRYTIAA-
LLSPYSYSTTAVVTNPKE-OH (Chloroacetyl-54 –99-c-102–127)
(IV)—The ligation reaction was initiated by mixing the two peptides,
bromoacetyl-102–127 TTR (I) (5.44 mg, 1.8 mmol) and chloroacetyl-54–
99-NH-CH2-CH2-SH (II) (6.84 mg, 1.26 mmol), in 1 ml of 6 M urea 0.1 M
NaHCO3, pH 8.3, under nitrogen. After mixing, the reaction mixture
was left to stand at room temperature for 24 h. Samples were with-
drawn at 0, 1, 2, and 20 h during this period for HPLC and ESMS
analysis. The ligated peptide IV was isolated from the reaction mixture
by semipreparative HPLC using a linear gradient of 0–70% B. The
fractions were analyzed by HPLC and ESMS; the fractions containing
the ligated peptide were then lyophilized. The purified peptide IV (6.01
mg) was characterized as the desired product IV by ESMS (observed
mass 5 8355 6 1.2; calculated for C379H572N92O117S1Cl1 5 8356.8
(average isotope composition)).
Chloro-Iodo Exchange of (IV) to give I-Ac-ELHGLTTEEEFVEG-
IYKVEIDTKSYWKALGISPFHEHAEVVFTAND-NH-CH2-CH2-S-CH2-
CO-PRRYTIAALLSPYSYSTTAVVTNPKE-OH (Iodoacetyl-54 –99-c-
102–127) (V)—Peptide IV (5.46 mg, 0.654 mmol) was dissolved in 8 M
urea 0.01 M NaOAc pH 7.5 (1 ml), and KI was added to saturation (;8
M). After placing under nitrogen, a sample was removed at 30 min,
purified by HPLC, and analyzed by ESMS to check completion of the
iodo exchange. The iodoacetyl peptide V was then purified by semi-
preparative HPLC and lyophilized to give 3.64 mg. The peptide was
characterized as the desired product V by ESMS (observed mass 5
8447 6 1.0; calculated for C379H572N92O117S1Cl1 5 8448.2 (average
isotope composition)).
Formation of H-GPTGTGESKAPLMVKVLDAVRGSPAINVA-
VHVFRKAADDTWEPFASGKTSE-NH-CH2-CH2-S-CH2-COELHGLT-
TEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTAND-NH-CH2-
CH2-S-CH2-CO-PRRYTIAALLSPYSYSTTAVVTNPKE-OH (1–51-c-
54–99-c-102–127 TR) (VI)—Ligation of the two peptides iodoacetyl-54–
99-NH-CH2-CH2-SH V (3.46 mg, 0.43 mmol) and 1–51-NH-CH2-
CH2-SH III (3.58 mg, 6.68 mmol) was initiated by mixing the two
peptides in 6 M urea, 0.2 M NaHCO3, pH 8.3 (500 ml) and placing under
nitrogen. The reaction was mixed and then left to stand at room tem-
perature for 5 h. Samples were withdrawn at 0, 1.5, and 4 h for HPLC
and ESMS analysis. The ligated peptide VI was isolated from the
reaction mixture by semipreparative HPLC using a linear gradient of
0–70% B. The fractions were analyzed by HPLC and ESMS; the frac-
tions containing the ligated peptide were then lyophilized to give VI
(2.76 mg). The purified peptide was characterized as the desired prod-
uct VI by ESMS (observed mass 5 13,676 6 1.3; calculated for
C615H949N158O189S3 5 13,676.4 (average isotope composition)).
Formation of the Tetrameric Complex—The ligated peptide (1–51-c-
54–99-c-102–127) (VI) (0.25 mg) was dissolved in 0.075 M NH4HCO3,
pH 8.3 (100 ml) and then diluted with 100 ml of H2O. To this solution
was added 5 ml of thyroxine T4 (5 mg/ml in 0.1 M NaOH). After equil-
ibrating at room temperature for 18 h, the tetrameric protein was
isolated by gel filtration on a Superdex 75 column (HR10/30; Amersham
Pharmacia Biotech; calibrated with phosphorylase, 97 kDa; bovine al-
bumin, 66 kDa; native TTR, 54 kDa; ovalbumin, 45 kDa; carbonic
anhydrase, 30 kDa; soya bean trypsin inhibitor, 20.1 kDa, and a-lac-
talbumin, 14.4 kDa) with 0.075 M NH4HCO3 10% CH3CN as the eluent
at 0.3 ml/min. The tetrameric protein was isolated at a retention time
of 22 min as determined by its equivalent retention time to that of
native TTR. It was kept in solution in the presence of excess T4 prior to
further analysis.
Western Analysis of Synthetic TTR—2 ml of human serum, 25 ml (0.5
mg) of sTTR solution, and 50 ml (1.0 mg) of sTTR were separated in a
0.1% SDS-polyacrylamide gel, using a stacking gel of 4.5% acrylamide,
pH 6.8, and a resolving gel of 15% acrylamide, pH 8.6 (34). Proteins
were transferred onto a nitrocellulose membrane, following which the
membrane was blocked. The primary antibody was 1:5000 antiserum
raised in a rabbit against a mixture of TTRs purified from serum from
human (Homo sapiens) wallaby (Macropus eugenii), and chicken (Gal-
lus gallus), and the secondary antibody was 1:10,000 anti-rabbit Ig
raised in sheep (Silenus), as described previously (35). Detection
achieved was using enhanced chemiluminescence against x-ray film.
Preparation of L-[125I]Thyroxine—Commercially available L-[125I]thy-
roxine was found to contain up to 5% 125I2 on the reference date.
Therefore, [125I]thyroxine was separated from 125I2 and other degrada-
tion products by reversed phase chromatography using a SepPak C-18
cartridge column (36). Purification was checked by thin layer chroma-
tography followed by autoradiography (37).
Analysis of Thyroxine Binding to Synthetic Human TTR—Commer-
cially purchased [125I]thyroxine was purified from degradation products
and 125I2 as described above. Methylcellulose charcoal was prepared as
described by Chang et al. (38). In order to remove thyroxine from the
solution containing sTTR, 40 ml of methylcellulose-charcoal (1%) in
Tris-HCl, pH 8.9, was centrifuged, and the supernatant was removed.
The methylcellulose-charcoal was resuspended in a 160-ml solution
containing 3.2 mg of sTTR. The mixture was kept at 4 °C for half an
hour, with mixing each 10 min. The solution was centrifuged, and the
supernatant was removed for analysis of [125I]thyroxine binding to
sTTR.
10 ml of human serum and 80 ml of solution containing sTTR (1.6 mg)
were incubated with 1.1 fmol (2.4 nCi) of purified [125I]thyroxine (room
temperature for 1 h), and a second aliquot of 80 ml of solution containing
sTTR (1.6 mg) was incubated with 4.4 fmol (9.6 nCi) of purified [125I]thy-
roxine (room temperature for 1 h). 5 ml of human serum and the total
amounts of sTTR solutions were analyzed by nondenaturing polyacryl-
amide gel electrophoresis, 10% acrylamide, 0.05 M Tris-HCl, pH 8.9,
4 °C (39) followed by autoradiography.
RESULTS
Synthetic Strategy—The choice of ligation sites for the prep-
aration of sTTR was based on both the amino acid sequence and
the known tertiary structure of the TTR molecule (Fig. 1, A and
B) and involved the ligation of three peptides (Fig. 1C). While
the ligation of two peptides, each of 60–65 residues in length,
is a possible alternative strategy, the degree of difficulty of
preparing and purifying peptides of this length is comparable
FIG. 1. A, sequence of human transthyretin 1–127 and depiction of
ligation points within the monomeric sequence. The chemoselective
thioether ligation sites are underlined. The cysteine at position 10 was
changed to Ala in the current synthesis. B, ribbon diagram of the TTR
monomer and tetramer showing the sites of chemical ligation in the
folded molecule. C, names and sequences of the three peptides synthe-
sized for the current study of sTTR.
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with the difficulty of a second ligation. In addition, since all of
the residues considered for future labeling studies occur within
the last 30 residues, it was desirable to prepare a relatively
small C-terminal fragment. It was anticipated that this ap-
proach would increase the ease of preparing several sTTR
molecules with selective labels, since only this fragment would
need to be resynthesized.
The thioether linker spans a distance equivalent to two
amino acids, is highly flexible, and is nonfunctionalized. While
Gly-Gly sequences are thus ideally suited as ligation points, the
TTR sequence contains no Gly-Gly site, although several Ser-
Gly sites are present at convenient positions. Two of these
Ser-Gly sites exist in loop positions within the TTR structure,
which were considered to be potentially more tolerant of sur-
rogate amide bonds than b-sheet or helical regions. Ser100-
Gly101 occurs in the loop between b-strands F and G, and
Ser52-Gly53 occurs in the loop between b-strands C and D.
Neither are close to the hormone binding site or at points of
intersubunit contact. A third Ser-Gly site (Ser46-Gly47) occurs
in the center of b-strand C and was ruled out as a potential
ligation point due to the likely disruption of the b-sheet by a
surrogate amide.
The selection of Ser52-Gly53 and Ser100-Gly101 ligation sites
required the synthesis of three peptides of 51, 46, and 26
residues. The ligation strategy for the three peptides is out-
lined in Fig. 2. The N-bromoacetylated 102–127 (peptide I) is
ligated to the N-chloroacetylated, C-thiolated 54–99 (peptide
II). The ligation proceeds preferentially between the thiol and
the bromoacetyl groups, so that polymerization of the peptide
II should not occur. The purified chloroacetylated 54–127 (pep-
tide IV) may then undergo simultaneous or sequential ex-
change to the iodoacetylated form (peptide V) and ligation with
C-thiolated 1–51 (peptide III) to produce fully ligated 1–127
(peptide VI).
In addition to nonnative bonds, one other modification was
made to sTTR. Cysteine 10 was replaced with alanine in order
to avoid any problems of competition for the iodoacetyl peptide
fragment during the ligation reaction and to exclude the pos-
sibility of oxidation when the protein was folded. Alanine was
chosen due to its similarity in bulk and hydrophobicity to
cysteine. This was considered unlikely to have any detrimental
effect on the folding or activity of TTR.
Peptide Synthesis and Purification—Trial syntheses of the
peptides I, II, and III were carried out to see how each of the
peptides would behave during the synthesis, cleavage, and
ligation reactions. This preliminary work showed that all three
peptides could be readily synthesized, cleaved from the resin,
and purified, excepting the middle fragment, which tended to
retain the methylphenoxyacetic acid (AMPA) linker at the C-
terminal thiol after HF treatment. This was detected as a
result of cleavage at the C-terminal amino acid attached to the
resin on which the peptide-AMPA linker was synthesized (see
“Experimental Procedures” for details). Despite this, the three
target peptides were obtained in good yield and purity.
Ligation of Peptides I and II—Ligation of peptides I and II
proceeded cleanly to give peptide IV (Fig. 2). The purification
and monitoring of the ligation reaction was complicated by the
fact that the ligated peptide IV co-elutes with the starting
peptide II; thus, the use of an excess of peptide I was required
to drive the reaction to completion. After 2 h, the starting
peptide II could not be detected, and the ligated peptide IV was
present in high yield as judged by HPLC and ESMS (Fig. 3, A
and B). The ligation was left overnight for completion of the
reaction. The broad HPLC profile of peptide II was attributed
to the chloroacetyl and the thiol functionalities at the N and C
termini of the peptide. The absence of the chloroacetyl group, in
particular, significantly reduces the broadness of the peak
shape.
Formation of the Iodoacetyl Peptide V—The initial chloro-
iodo exchange reaction and the subsequent ligation were car-
ried out in situ (peptide III was added to peptide IV in satu-
rated KI solution). Most of the thiol peptide III was found to
form disulfide dimers, and the iodoacetyl peptide V also lost a
small percentage of its iodofunctionality. In subsequent liga-
tions, the iodoacetyl peptide V was either purified by RP-HPLC
and the ligation reaction was carried out immediately after
lyophilization, or it was purified by rapid desalting using a
PD10 column (Amersham Pharmacia Biotech) followed by
ligation.
Ligation of Peptides III and V to Give VI—After purification
of the iodoacetyl peptide V, its ligation to peptide III (1–51
TTR) was carried out as rapidly as possible under nitrogen.
Samples were removed from the ligation mixture and analyzed
by HPLC and ESMS. The rate of the ligation reaction, affording
the ligated 1–127 TTR VI, was monitored by a slow HPLC
gradient (0.5%/min B) as the ligated product eluted very close
to the two starting peptides (III and V) and the disulfide-linked
peptide formed by the unreacted excess of peptide III (Fig. 4A).
The ligated 1–127 peptide VI was easily purified by RP-HPLC
in excellent yield, and its identity was confirmed by ESMS (Fig.
4B).
Folding of Synthetic TTR to Give the 54-kDa Tetrameric
FIG. 2. Ligation scheme for the syn-
thesis of transthyretin showing the
three-step process to give synthetic
transthyretin.
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Complex—The sTTR spontaneously folded to its tetramer com-
plex in the presence of the ligand T4, in 0.075 M NH4HCO3. In
addition to the formation of tetramer (as initially determined
by its equivalent retention time to that of native TTR upon size
exclusion chromatography), two other products were also
formed. These corresponded to species with an intermediate
molecular weight, likely to be a dimeric form of sTTR, as well as
a high molecular weight aggregated sTTR (Fig. 5, top trace).
The ratio of these products altered over time in the refolding
buffer, with a gradual accumulation of the high molecular
weight aggregate. After isolating the tetrameric complex, it
was equilibrated at 37 °C for 48 h in the presence of excess T4
ligand. Some reequilibration between the monomeric, tet-
rameric, and high molecular weight aggregates occurred in the
initial 2 h, but the ratios of tetramer to monomer and the high
molecular weight aggregates remained constant after that time
(Fig. 5, bottom trace).
Western Analysis of Synthetic TTR—Western analysis was
employed to determine the subunit molecular mass and con-
firm the recognition of the sTTR by anti-TTR antiserum (Fig.
6). An aliquot of human serum was analyzed as a positive
control. TTR has a subunit molecular mass of ;15 kDa, as
estimated by SDS-polyacrylamide gel electrophoresis (39). The
interactions between monomers to form the dimer are very
strong, and even after boiling in the presence of 2% SDS for 20
min, some TTR still exists as a dimer (38). Thus, bands with
molecular masses of about 15 and of about 34 kDa correspond
to the TTR monomer and dimer, respectively. Bands are also
apparent at higher molecular masses. These result from non-
specific binding of the antibodies to other proteins in serum as
is commonly observed (35).
Synthetic TTR gave rise to bands corresponding to the mo-
lecular masses of the sTTR monomer and dimer (Fig. 6, lanes 2
and 3). The bands were discrete, and no indication of partially
synthesized or partially degraded sTTR was apparent.
Analysis of Thyroxine Binding to Synthetic TTR—The cor-
rect folding and formation of the tetramer was assessed by
FIG. 5. Gel filtration profiles of the solution used for folding
the ligated synthetic transthyretin VI. An Amersham Pharmacia
Biotech Superdex 75 10/30 column used 0.075 M NH4HCO3, pH 8.3,
with 10% CH3CN and a flow rate of 0.3 ml/min. The protein was
detected at 214 nm. The top trace shows the protein VI (3.65 nM) after
18 h at room temperature in 0.375 M NH4HCO3 with 0.5 equivalents of
T4 (excess T4 precipitates from solution). The bottom trace shows the
isolated synthetic transthyretin VI tetrameric complex after reequili-
bration at 37 °C for 48 h. Monomeric and dimeric species, as ascertained
by their retention time, are indicated.
FIG. 3. A, HPLC traces showing the
peptide ligation mixture for peptides I
and II at time 0 (top) and 2 h (bottom).
The resultant ligated peptide IV elutes at
the same position that the starting pep-
tide II elutes. B, the mass spectrum of the
peak for peptide IV, showing the forma-
tion of the ligated peptide. *, daughter
ions of starting peptide II still present
after 2 h. Inset, mass spectrum recon-
struct showing the correct mass for the
ligated peptide IV.
FIG. 4. A, HPLC traces showing the
peptide ligation mixture for peptides III
and V at time 0 (above) and 2 h (below). B,
the mass spectrum of a sample of the peak
for the ligated peptide VI, 1–127. Inset,
mass spectrum reconstruct showing the
correct mass for the ligated synthetic
TTR, peptide VI (13,675 Da), as well as
the presence of a deletion product (13,522
Da).
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analyzing nondenaturing polyacrylamide gel migration com-
bined with a [125I]thyroxine binding assay. The analysis of
[125I]thyroxine binding to proteins in human serum was used
as the reference. This revealed the presence of thyroxine-bind-
ing globulin, albumin, and TTR (Fig. 7, lanes 1 and 4). The
binding of [125I]thyroxine by sTTR was clearly demonstrated in
both the aliquots of 80 ml of solution containing 1.6 mg of sTTR,
following incubation with both 1 ml (1.1 fmol) and 4 ml (4.4 fmol)
of [125I]thyroxine (Fig. 7, lanes 2 and 3, respectively). The
position of migration was almost identical to that in serum,
indicating that the tetrameric size, shape, and charge distribu-
tion of sTTR were almost identical to native TTR. There was no
evidence for the existence of aggregates.
DISCUSSION
We have shown that it is possible to chemically synthesize
and correctly fold a transthyretin analog (sTTR) from its mo-
nomeric unfolded state to produce the 54-kDa tetrameric qua-
ternary structure in the presence of TTR’s strongest binding
native ligand, T4. This is probably due to the stabilizing effect
of T4, which has previously been reported to stabilize native
TTR against acid denaturation, leading to the formation of
amyloid fibrils (15). The integrity of the final product was
confirmed by native TTR antibody recognition and ligand bind-
ing studies. Since the binding site for thyroid hormone ligands
is formed only upon the formation of the tetrameric species,
ligand binding also demonstrated tetramer formation.
Competing folding pathways involving the formation of high
molecular weight aggregate as well as the appearance of
smaller molecular weight species, possibly corresponding to
dimeric and monomeric sTTR, were also apparent. The former
pathway was expected, considering the predisposition for TTR
to form amyloid fibrils and, in particular, the increased pro-
pensity of many mutant forms of TTR to do so. The appearance
of dimeric-like species of sTTR, however, was unexpected, since
this species has never previously been reported. The current
model of the unfolding pathway of TTR involves a transition
between correctly folded TTR to its monomeric form via a
perturbed tetramer and an extremely transient dimeric form
(40). The monomeric TTR is thought to be in equilibrium with
a molten globule-like monomeric structure or to be sequestered
to irreversible amyloid formation. Our refolding studies of
sTTR have revealed a species that appears to have the molec-
ular weight of the dimeric form of sTTR. It was not possible to
isolate this dimeric species for further identification. Rechro-
matographing the species using gel diffusion chromatography
only gave rise to the high molecular weight aggregate and some
of the monomeric species. This highly unstable form may be
unique to sTTR or represent an alternative species that could
be the basic unit of TTR-based amyloid fibrils.
It is not surprising that the sTTR construct has a high
propensity to form aggregates. Investigations into mutant
forms of TTR have shown that even in the absence of apparent
perturbations to the tertiary and quaternary structure of TTR,
most mutant forms of TTR display a higher propensity to form
amyloid fibril than native TTR (41–43). The mutations, rather
than underlying an alternative TTR conformation, are thought
to cause subtle perturbations to the equilibrium between the
different forms of TTR. Any such movement toward the mono-
meric form of TTR thus results in the increased opportunity for
TTR monomer to be irreversibly incorporated into amyloid.
FIG. 6. Western analysis for the presence of transthyretin in
human serum and in solution containing synthetic transthyre-
tin. Samples were separated in an SDS-polyacrylamide gel, and then
proteins were transferred onto a nitrocellulose membrane and probed
with antiserum against a mixture of transthyretins purified from hu-
man, wallaby, and chicken sera (raised in a rabbit), and the secondary
antibody was anti-rabbit Ig (raised in sheep). Detection was performed
using enhanced chemiluminescence (see “Experimental Procedures” for
details). Lane 1, 2 ml of human serum; lane 2, 25 ml of solution contain-
ing 0.5 mg of synthetic transthyretin; lane 3, 50 ml of solution containing
1.0 mg of synthetic transthyretin. Molecular weight markers (3 1023)
were “Mark 12” from Novex: b-galactoside, 116.3; phosphorylase b,
97.4; serum albumin, 66.3; glutamic dehydrogenase, 55.4; lactate dehy-
drogenase, 36.5; carbonic anhydrase, 31; trypsin inhibitor, 21.5; ly-
sozyme, 14.4; aprotinin, 6; insulin B chain, 3.5; and insulin A chain, 2.
The positions of the origin and migration of transthyretin dimer, tran-
sthyretin monomer, and the electrophoretic front are indicated.
FIG. 7. Analysis of thyroxine binding to proteins in human
serum and to synthetic transthyretin. Aliquots of human serum (10
ml) and of synthetic TTR solution (80 ml containing 1.6 mg) were incu-
bated with [125I]thyroxine prior to separation in a nondenaturing poly-
acrylamide gel, pH 8.6. The gel was dried and then exposed to autora-
diographic film for 7 days (see “Experimental Procedures”). Lane 1, 5 ml
of human serum; lanes 2 and 3, 80 ml of solution containing 1.6 mg of
synthetic transthyretin with 1.1 and 4.4 fmol of [125I]thyroxine respec-
tively; lane 4, 5 ml of human serum. The positions of migration of human
thyroxine-binding globulin (TBG), albumin, and transthyretin (TTR)
are indicated. The positions of the origin and front of the gel are also
indicated.
Chemical Synthesis and Folding of TTR26002
 at UQ Library on October 25, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
As observed for native TTR, the tetrameric form of sTTR is
its most stable form. Early studies of recombinant TTR and
TTR isolated from serum showed that it is very difficult to
dissociate the tetrameric structure into its monomeric sub-
units. TTR was reported as stable in chaotropic solutions of 8 M
urea and 6 M guanadinium hydrochloride (7). More recent stud-
ies of the denaturation pathway of recombinant TTR showed
that the tetrameric unit does not begin to dissociate into un-
folded monomer until the chaotrope concentration exceeds 4 M
guanadinium hydrochloride (44). Fully unfolded recombinant
TTR (denatured in 7 M guanadinium hydrochloride) does not
refold until the denaturant concentration has dropped well
below 2 M guanadinium hydrochloride, showing that the tet-
rameric TTR structure is kinetically highly stable.
In the current study, sTTR could not be refolded by slowly
decreasing the denaturant concentration by dialysis. This only
led to the formation of high molecular weight aggregates. sTTR
did, however, fold to the tetrameric structure at a low salt
concentration in the presence of the native T4 ligand. Folding
the protein using ligands more soluble than T4 such as 3,5,39-
triiodothyronine, 39,59,3-triiodothyronine, diiodothyronine, and
thyronine did not give rise to the tetrameric form of the protein.
This may have been due to the lower Kd of these ligands to TTR
relative to the T4 ligand, thereby not stabilizing the sTTR
complex to the same degree as the T4 ligand.
It is not known whether the sTTR tetramer forms and then
is stabilized by T4 or the tetramer spontaneously forms about
the T4. The stabilization of sTTR by a high affinity ligand,
however, appears analogous to the stabilization observed for
TTR in the presence of several nonsteroidal anti-inflammatory
drugs currently under investigation for their ability to inhibit
human transthyretin amyloid disease (17). These molecules,
which include flufenamic acid, diclofenac, and flurbiprofen,
bind in the T4 binding site of TTR (45), forming similar polar
and nonpolar contacts as do the natural ligands. These inter-
actions are thought to stabilize the native quaternary structure
of TTR against pH-mediated dissociation and conformational
changes associated with amyloid formation (16). It may be that
some of these drugs would also promote the folding of sTTR
from its unfolded monomeric state.
In conclusion, the current study reports a methodology for
the total chemical synthesis of a TTR analog (sTTR) through
use of a thioether strategy for the sequential ligation of three
peptides and successful folding and formation of the sTTR
tetramer in the presence of the native ligand T4. It is remark-
able that this macromolecule can be synthesized, however,
since other multimeric forms of sTTR also formed readily, the
construct may not be not ideal for biophysical studies. It is
possible that other TTR analogs made using thioether linkages
placed in alternative positions may provide closer mimics of
native structure. Such constructs potentially allow the incor-
poration of 15N or 13C isotopic labels at TTR ligand binding
sites and may facilitate future TTR-ligand studies using NMR
spectroscopy. In particular, the kinetics of the interaction be-
tween sTTR and TTR-binding drugs of current interest for
their antiamyloidogenic capacity may be carried out in the
presence of other competitive binding proteins to provide a
more complete picture of their mode of action in serum.
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